Joshua A Barocas1, Elizabeth Blackstone, Tara C Bouton, Simeon D Kimmel, Andrea Caputo, Sarah J Porter, Alexander Y Walley. 1. Section of Infectious Diseases, Boston Medical Center, Boston, MA (BMC) (JAB, TCB, SDK); Boston University School of Medicine, Boston, MA (JAB, TCB, SDK); Victory Programs, Inc, Boston, MA (EB, SJP); Department of Medicine, Clinical Addiction Research and Education Unit, Section of General Internal Medicine, Boston University School of Medicine and BMC, Boston, MA (SDK, SDK, AYW); Grayken Center for Addiction, BMC, Boston, MA (JAB, SDK, SDK, AYW).
Abstract
OBJECTIVES: The global pandemic of coronavirus disease 2019 (Covid-19) may disproportionately affect persons in congregate settings, including those in residential substance use treatment facilities. To limit the spread of SARS-CoV-2 through congregate settings, universal testing may be necessary. We aimed to determine the point prevalence of SARS-CoV-2 in a residential treatment program setting and to understand the unique challenges of Covid-19 transmission in this setting. METHODS: We performed a case series of SARS-CoV-2 rT-PCR testing via nasopharyngeal in a residential substance use treatment program for women in Boston. Staff and residents of the treatment program were tested for SARS-CoV-2. The primary outcome was SARS-CoV-2 test result. RESULTS: A total of 31 residents and staff were tested. Twenty-seven percent (6/22) of the residents and 44% (4/9) of staff tested positive for SARS-CoV-2. All of the SARS-CoV-2 positive residents resided in the same residential unit. Two positive cases resided together with 2 negative cases in a 4-person room. Two other positive cases resided together in a 2-person room. One positive case resided with 2 negative cases in a 3-person room. One positive case resided with a negative case in a 2-person room. Based on test results, residents were cohorted by infection status and continued to participate in addiction treatment on-site. CONCLUSIONS: SARS-CoV-2 infection was common among staff and residents within a residential substance use treatment program for women in Boston. Universal SARS-CoV-2 testing in residential substance use programs can be instituted to reduce the risk of further transmission and continue addiction treatment programming when accompanied by adequate space, supplies, and staffing.
OBJECTIVES: The global pandemic of coronavirus disease 2019 (Covid-19) may disproportionately affect persons in congregate settings, including those in residential substance use treatment facilities. To limit the spread of SARS-CoV-2 through congregate settings, universal testing may be necessary. We aimed to determine the point prevalence of SARS-CoV-2 in a residential treatment program setting and to understand the unique challenges of Covid-19 transmission in this setting. METHODS: We performed a case series of SARS-CoV-2 rT-PCR testing via nasopharyngeal in a residential substance use treatment program for women in Boston. Staff and residents of the treatment program were tested for SARS-CoV-2. The primary outcome was SARS-CoV-2 test result. RESULTS: A total of 31 residents and staff were tested. Twenty-seven percent (6/22) of the residents and 44% (4/9) of staff tested positive for SARS-CoV-2. All of the SARS-CoV-2 positive residents resided in the same residential unit. Two positive cases resided together with 2 negative cases in a 4-person room. Two other positive cases resided together in a 2-person room. One positive case resided with 2 negative cases in a 3-person room. One positive case resided with a negative case in a 2-person room. Based on test results, residents were cohorted by infection status and continued to participate in addiction treatment on-site. CONCLUSIONS: SARS-CoV-2 infection was common among staff and residents within a residential substance use treatment program for women in Boston. Universal SARS-CoV-2 testing in residential substance use programs can be instituted to reduce the risk of further transmission and continue addiction treatment programming when accompanied by adequate space, supplies, and staffing.
Authors: Sharon Reif; Preethy George; Lisa Braude; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon Journal: Psychiatr Serv Date: 2014-03-01 Impact factor: 3.084
Authors: Sean Wei Xiang Ong; Yian Kim Tan; Po Ying Chia; Tau Hong Lee; Oon Tek Ng; Michelle Su Yen Wong; Kalisvar Marimuthu Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Emily Mosites; Erin M Parker; Kristie E N Clarke; Jessie M Gaeta; Travis P Baggett; Elizabeth Imbert; Madeline Sankaran; Ashley Scarborough; Karin Huster; Matt Hanson; Elysia Gonzales; Jody Rauch; Libby Page; Temet M McMichael; Ryan Keating; Grace E Marx; Tom Andrews; Kristine Schmit; Sapna Bamrah Morris; Nicole F Dowling; Georgina Peacock Journal: MMWR Morb Mortal Wkly Rep Date: 2020-05-01 Impact factor: 17.586
Authors: Temet M McMichael; Dustin W Currie; Shauna Clark; Sargis Pogosjans; Meagan Kay; Noah G Schwartz; James Lewis; Atar Baer; Vance Kawakami; Margaret D Lukoff; Jessica Ferro; Claire Brostrom-Smith; Thomas D Rea; Michael R Sayre; Francis X Riedo; Denny Russell; Brian Hiatt; Patricia Montgomery; Agam K Rao; Eric J Chow; Farrell Tobolowsky; Michael J Hughes; Ana C Bardossy; Lisa P Oakley; Jesica R Jacobs; Nimalie D Stone; Sujan C Reddy; John A Jernigan; Margaret A Honein; Thomas A Clark; Jeffrey S Duchin Journal: N Engl J Med Date: 2020-03-27 Impact factor: 91.245